Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination

Overtreatment of patients with ductal carcinoma in situ (DCIS) is driven by a lack of a reliable prognostic biomarker. Widespread mammographic screening has resulted in a substantial increase in women diagnosed with DCIS. To improve patient risk stratification, we investigate circulating tumor cells (CTCs) as a biomarker for DCIS patients' biological aggressiveness and as an indicator of early dissemination. We apply microfluidics to enrich CTCs from 34 patients with DCIS and find a significantly higher concentration of CTCs compared to in healthy controls. We profile CTCs and matched DCIS tissues using single-cell RNA sequencing. We find that CTCs express higher clonal aberrations when compared to white blood cells from the same samples, and clonal comparisons between matched tissue and CTC samples provide evidence for an evolutionary bottleneck model. mRNA expression in CTC reveals EMT/MET and immunoregulatory pathway regulation with a suggestion of racial differences. Last, we provide support for early dissemination in DCIS using a Mouse IntraDuctal model.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2025-10-29
DOI
https://doi.org/10.1126/sciadv.adz0187
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination

Sunitha Nagrath, Ashley Huppe, Fariba Behbod, Camron Smith et al.
Science Advances
Cancer Cells and Metastasis
article

Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination

Sunitha Nagrath, Ashley Huppe, Fariba Behbod, Camron Smith, Andrew K. Godwin, Christa Balanoff, Jamie Wagner, Neha Nagpal, Kelsey E. Larson, Brittany Rupp, Allison M. Aripoli, Carol J. Fabian, Max S. Wicha, Jessica Peterson, Onalisa Winblad, Yan Hong, Timothy A. Fields, Molly Hill
article en

Abstract

Overtreatment of patients with ductal carcinoma in situ (DCIS) is driven by a lack of a reliable prognostic biomarker. Widespread mammographic screening has resulted in a substantial increase in women diagnosed with DCIS. To improve patient risk stratification, we investigate circulating tumor cells (CTCs) as a biomarker for DCIS patients' biological aggressiveness and as an indicator of early dissemination. We apply microfluidics to enrich CTCs from 34 patients with DCIS and find a significantly higher concentration of CTCs compared to in healthy controls. We profile CTCs and matched DCIS tissues using single-cell RNA sequencing. We find that CTCs express higher clonal aberrations when compared to white blood cells from the same samples, and clonal comparisons between matched tissue and CTC samples provide evidence for an evolutionary bottleneck model. mRNA expression in CTC reveals EMT/MET and immunoregulatory pathway regulation with a suggestion of racial differences. Last, we provide support for early dissemination in DCIS using a Mouse IntraDuctal model.

Science AdvancesVol. 11(44)
Virginia Commonwealth University (US), University of Michigan (US), University of Kansas Medical Center (US), BioSurfaces (United States) (US)
Openalex Percentile: Top 58%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.